GLP-1 Agonist Therapy Center

Battle between two GLP-1 receptor agonists proves semaglutide achieves favorable HbA1c levels, decreased mean body weight.

Why patients are not seeing results when it comes to adhering to treatment plans.

Once-weekly injectable suspension can provide as much benefit as traditional twice-daily dosing.

Study compares effectiveness of oral GLP-1 medication over injection.

New study suggests improvement in quality of life and obesity seen with liraglutide compared with placebo.

Once-weekly exenatide formulation can provide as much benefit as the traditional twice-daily dosing.

The FDA has approved an auto-injector and new formulation of a once-weekly treatment for type 2 diabetes from AstraZeneca. Bydureon BCise offers a single-dose auto-injector for adults with type 2 diabetes. Bydureon BCise features a unique continuous-release microsphere technology delivery system that provides consistent levels of the product’s active ingredient, exenatide. The new formulation has shown the ability to reduce blood sugar levels alongside weight loss, despite not being a weight loss medication.

Patients with type 2 diabetes not responding to basal insulin therapy alone may see glycemic improvement with a GLP-1 receptor agonist.

Trial finds improvement in control and weight loss.

I have had several patients who did well at first with their GLP-1 agonists. Patient 1: Man, 46 years of age, used liraglutide 3mg daily for obesity. Patients 2 & 3: 2 women in their 60s were using liraglutide for type 2 diabetes & weight.